GlycoMimetics(GLYC) - 2025 Q3 - Quarterly Results

1 Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pipeline, with IND Submission for CR-002 on Track for Mid-2026 Waltham, Mass., November 6, 2025 – Crescent Biopharma, Inc. ("Crescent" or the "Company") (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advan ...